Takeda Updates HEMOFIL® M and RECOMBINATE Availability for Hemophilia A Patients

Takeda Updates HEMOFIL® M and RECOMBINATE Availability for Hemophilia A Patients

The National Bleeding Disorders Foundation (NBDF) is alerting the community to updated information from Takeda Pharmaceutical Company regarding the discontinuation timelines for HEMOFIL® M and RECOMBINATE®, two therapies used to treat hemophilia A,

National Bleeding Disorders Foundation’s Matt Delaney Named City & State New York’s 2026 Albany 40 Under 40 List

National Bleeding Disorders Foundation’s Matt Delaney Named City & State New York’s 2026 Albany 40 Under 40 List
Government Relations Manager recognized as a rising star in New York State politics and advocacy, a journey that began with NBDF programs.